Get the Stockscreener App
12.02
0.42%
0.05
Kura Oncology Inc stock is traded at $12.02, with a volume of 1.08M.
It is up +0.42% in the last 24 hours and up +20.68% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$11.97
Open:
$12
24h Volume:
1.08M
Relative Volume:
0.57
Market Cap:
$1.05B
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-5.5392
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
+0.25%
1M Performance:
+20.68%
6M Performance:
+86.36%
1Y Performance:
+9.87%
1-Day Range:
$11.95
$12.32
1-Week Range:
$10.80
$12.32
52-Week Range:
$5.41
$12.49
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
4930 DIRECTORS PLACE, SUITE 500, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
12.02 | 1.04B | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Neutral |
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
FDA approved five NMEs in November - biocentury.com
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - The Malaysian Reserve
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
Kura Oncology (NASDAQ:KURA) Trading Up 7.3%What's Next? - MarketBeat
Kura Oncology: A Cautious Buy (NASDAQ:KURA) - Seeking Alpha
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia - The Manila Times
Kura Oncology to Host Virtual Investor Event to Discuss - GlobeNewswire
Geode Capital Management LLC Purchases 211,470 Shares of Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology (KURA) Is Down 7.2% After First KOMZIFTI Sale Triggers $135M Milestone Payment - simplywall.st
Kura Oncology: Expect Volatility Following Ziftomenib Phase 1b Data (NASDAQ:KURA) - Seeking Alpha
Kura Oncology, Inc. Completes Collaboration and License Agreement with Kyowa Kirin - marketscreener.com
Kura Oncology Expects $135 Million Milestone Payment for First US Sale of Komzifti - marketscreener.com
Kura Oncology (KURA) Secures $135 Million Milestone with KOMZIFT - GuruFocus
Kura Oncology completes first commercial sale of leukemia drug - Investing.com
Kura Oncology completes first U.S. commercial sale of KOMZIFTI - TipRanks
Kura Oncology announces first US sale of KOMZIFTI, triggering $135 million payment - Investing.com
Kura Oncology Announces First U.S. Sale of KOMZIFTI - TipRanks
Kura Oncology completes first commercial sale of leukemia drug By Investing.com - Investing.com India
First U.S. commercial sale of Komzift triggers $135 million milestone payment to Kura Oncology - MarketScreener
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin - The Manila Times
Kura Oncology (Nasdaq: KURA) to receive $135M as KOMZIFTI launches in U.S. market - Stock Titan
First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 - GlobeNewswire
How Kura Oncology Inc. stock trades during market volatilityRate Hike & Daily Growth Stock Investment Tips - Newser
How geopolitical tensions affect Kura Oncology Inc. stockWeekly Stock Report & Technical Confirmation Trade Alerts - Newser
How rising interest rates impact Kura Oncology Inc. stock - Newser
What drives Kura Oncology Inc stock priceSector Performance Drivers & Swing Trade Smarter With Data Insights - earlytimes.in
Magnetar Financial LLC Buys 64,345 Shares of Kura Oncology, Inc. $KURA - MarketBeat
KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML) - The Manila Times
Kura Oncology’s leukemia drug added to NCCN treatment guidelines By Investing.com - Investing.com Australia
Kura Oncology’s leukemia drug added to NCCN treatment guidelines - Investing.com UK
Kura Oncology stock rises after KOMZIFTI added to NCCN treatment guidelines - Investing.com Canada
Kura Oncology and Kyowa Kirin's KOMZIFTI™ Approved and Included in NCCN Guidelines for Treatment of Relapsed/Refractory AML with NPM1 Mutation - Quiver Quantitative
KOMZIFTI™ (ziftomenib) Added to National Comprehensive - GlobeNewswire
Kura Oncology (NASDAQ: KURA) KOMZIFTI Named NCCN Category 2A Option for R/R NPM1 AML - Stock Titan
Kura Oncology (KURA) Is Up 8.1% After FDA Approval of KOMZIFTI for NPM1-Mutated AML – What's Changed - Yahoo Finance
Barclays Remains a Buy on Kura Oncology (KURA) - The Globe and Mail
Barclays Raises Price Target for Kura Oncology (KURA) to $28 | K - GuruFocus
Barclays Maintains Kura Oncology (KURA) Overweight Recommendation - MSN
KURA Stock Rises Pre-Market After Receiving Milestone Payment Related To Cancer Drug Development Agreement - MSN
Is Kura Oncology Inc a good long term investmentMarket Entry Points & Free Exceptional Risk Adjusted Gains - earlytimes.in
Why The Narrative Around Kura Oncology Is Shifting After FDA Approval and Analyst Upgrades - Yahoo Finance
(KURA) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Will Kura Oncology Inc. stock benefit from infrastructure spendingQuarterly Growth Report & Stock Timing and Entry Methods - newser.com
How Kura Oncology Inc. stock performs in high volatility marketsEarnings Growth Summary & Long-Term Safe Investment Plans - newser.com
Kura Oncology at Jefferies Conference: Strategic Insights on Zypto By Investing.com - Investing.com Canada
Can Kura Oncology Inc. stock resist market sell offs2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Is Kura Oncology Inc. showing signs of accumulationQuarterly Market Summary & High Return Stock Watch Alerts - newser.com
Is Kura Oncology Inc. stock recession proofJuly 2025 Summary & Free Long-Term Investment Growth Plans - newser.com
How to monitor Kura Oncology Inc. with trend dashboards2025 Risk Factors & AI Powered Market Entry Strategies - newser.com
Candlestick signals on Kura Oncology Inc. stock todayJuly 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Can Kura Oncology Inc. stock resist sector downturnsRecession Risk & Daily Growth Stock Investment Tips - newser.com
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):